Module 1: CML Therapy

Giuseppe SaglioChair:
Professor Giuseppe Saglio (Italy)

Qian JiangCo-chair:
Professor Qian Jiang (China)

Chair's Overview

Professor Giuseppe Saglio

Professor of Internal Medicine and Haematology
Department of Clinical and Biological Sciences
University of Turin
Turin, Italy

Frontline Therapy

Professor Jorge Cortes

Director, Georgia Cancer Center
Cecil F. Whitaker Jr., GRA Eminent Scholar Chair in Cancer
Augusta, USA

When Frontline Therapy Fails and Beyond the Second Line Therapy

Jeff Lipton

 Dr Jeff Lipton

University of Toronto and
Princess Margaret Cancer Centre
Toronto, Canada

 

Beyond the Chronic Phase

Susanne Saussele

Professor Susanne Saussele

Head, CML Excellence Center
Hematology and Oncology
University of Mannheim
Germany

 

ELN Recommendations and How These Have Evolved Over 15 Years

professor doctor andreas hochhaus

Professor Andreas Hochhaus

Professor of Internal Medicine, Hematology and Oncology
University Medical Centre
Jena, Germany

 

How are these recommendations amended to reflect local needs in low and middle-income countries?

Leading haematologists from low and middle-income countries talk with Dr Arlene Harriss-Buchan, from the iCMLf, about the challenges of adapting the ELN recommendations to provide best practice CML therapy in resource constrained environments.

Amha Gebremedhin
Qian Jiang

A perspective from China

Qian Jiang

Professor Qian Jiang

Professor, Deputy Chair, Department of Hematology
Peking University People’s Hospital
Peking University Institute of Hematology
Beijing, China

 

A perspective from Nepal

Dr Mipsang Lama

Assistant Prof, MBBS, MD (Internal Medicine)
PDF (Clinical Hematology and BMT)
Patan Hospital, Lalitpur, Nepal.

 

A perspective from Mexico

Dr Rafael Hurtado

Head of Hematology
Hospital Angeles
Pedregal, Mexico City, Mexico

 

A perspective from Ethiopia

Amha Gebremedhin

Associate Professor Amha Gebremedhin

Associate Professor of Medicine
Consultant in Internal Medicine and Hematology
Department of Internal Medicine
School of Medicine, College of Health Sciences
Addis Ababa University
Addis Ababa, Ethiopia

 

Discussion

Do you have any questions, or comments for the speakers, or community?
Leave your comments below and we will contact the presenter for a reply.

To prevent spam all comments will be forwarded to an admin who will approve the comments and arrange a reply if appropriate.

Subscribe
Notify of
guest
2 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments
Anonymous
Anonymous
2 months ago

A 38 year old male, in a routine physical exam detected a very high WBC (197k), RBC, Hemoglobin and Platelets are okay. Completely asymptomatic.
On further examination, RT qPCR BCR ABL major p210 is detected at 0.1385% MR 2.86 before treatment.
Hypercellur bone marrow 100% cellularity, with left shifted granulocytic hyperplasia and mildly increased easinophils.
Blasts 0.4%, Myeloid 94.9% in Flow Cytometry Differential.
Lab results indicate CML in chronic phase, but how it’s possible to have this low percentage of BCR-ABL before the treatment (0.1385%)?

Ehab Atallah
Ehab Atallah
Reply to  Anonymous
2 months ago

I agree with you, it is very unusual to have this very low level BCR-ABL at diagnosis, with this amount of disease. I am assuming the karyotype did demonstrate the Philadelphia chromosome. I can think of two possibilities:
1. A lab error, and would suggest repeating the test
2. BCR-ABL variant, and would suggest a qualitative test for p190, p230, and other rare variants (maybe done at Mayo clinic)

Thanks,
Ehab Atallah (Wisconsin, USA)